Reviva Announces Full Details of Positive Phase 2 Clinical Trial Results for Acute Schizophrenia

Apr 26, 2021 | Press Releases

Met endpoints for safety and efficacy in 234 patients’ clinical trial with Acute Schizophrenia or Schizoaffective DisorderMet primary endpoint of reduction in Positive and Negative Syndrome Scale (PANSS) total score for SchizophreniaMitigated positive symptoms...

Reviva Pharmaceuticals Holdings, Inc. Reports 2020 Financial Results and Provides Corporate Update

Mar 22, 2021 | Press Releases

-Closed Merger with Tenzing Acquisition Corp and publicly listed on NASDAQ Capital Market- -Plans to initiate a pivotal Phase 3 trial in schizophrenia in mid-2021, assuming fundraising goals achieved- CUPERTINO, Calif., March 22, 2021 — Reviva Pharmaceuticals...

Reviva Pharmaceuticals Holdings, Inc. to Present at the Maxim Group Inaugural 2021 Emerging Growth Virtual Conference

Mar 11, 2021 | Press Releases

CUPERTINO, Calif., March 11, 2021 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet...

Reviva Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

Mar 4, 2021 | Press Releases

CUPERTINO, Calif., March 04, 2021 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva”) today announced that its wholly owned subsidiary Reviva Pharmaceuticals, Inc., a clinical-stage pharmaceutical company...

Reviva Pharmaceuticals, Inc. and Tenzing Acquisition Corp. Complete their Business Combination and Trade as Reviva Pharmaceuticals Holdings, Inc.

Dec 14, 2020 | Press Releases

Combined Company to Trade on NASDAQ Post-closing under Tickers: RVPH and RVPHW NEW YORK and CUPERTINO, Calif., Dec. 14, 2020 — Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation (“Reviva Holdings”), as the successor to Tenzing Acquisition...